CSIMarket Company Name, Ticker, Competitors, else..
 
Telomir Pharmaceuticals Inc   (NASDAQ: TELO)
 
Price: $1.1800 $0.01 0.855%
Day's High: $1.2200000286102295 Week Perf: -1.67 %
Day's Low: $ 1.17 30 Day Perf: 5.36 %
Volume (M): 59,144 52 Wk High: $ 2.09
Volume (M$): $ 0 52 Wk Avg: $1.30
Open: $1.17 52 Wk Low: $0.89



 Market Capitalization (Millions $) 72
 Shares Outstanding (Millions) 61
 Employees 2
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a preclinical-stage pharmaceutical firm developing novel small-molecule therapeutics targeting age-related diseases and oncology. Its lead investigational candidate, Telomir-1, is designed to regulate intracellular metal ion homeostasis to influence biological mechanisms associated with aging and cancer. The company is conducting preclinical research and intends to advance Telomir-1 through clinical trials and regulatory approvals.


   Company Address: 100 SE 2nd St Miami 33131 FL
   Company Phone Number: 396-6723   Stock Exchange / Ticker: NASDAQ TELO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GERN   -4.76%    
OMER   -7.32%    
• View Complete Report
   



Clinical Study

Telomir Pharmaceuticals Joins Russell 3000 and Microcap Indexes, Strengthening Position in Pharmaceutical Market

Published Tue, Jul 2 2024 12:30 PM UTC

TAMPA, Fla., July 02, 2024 - Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company specializing in the development and commercialization of Telomir-1, a revolutionary small molecule aimed at lengthening the protective telomere caps of DNA, has been included as a member of the prestigious Russell 3000 and Russell Microcap Indexes. This lat...
Clinical Study

Telomir Pharmaceuticals Achieves Crucial Milestones in Safety Evaluation of Telomir-1 o...

Published Thu, May 30 2024 12:30 PM UTC

Telomir Pharmaceuticals, a leading biopharmaceutical company, is thrilled to announce two significant milestones in the development of their flagship product candidate, Telomir-1. The company has commenced a groundbreaking study to evaluate the safety of Telomir-1 when administered orally to geriatric laboratory beagle dogs for 63 consecutive days, marking a crucial step tow...
Clinical Study

Telomir-1: Unlocking the Secrets of Cellular Aging -Telomir Pharmaceuticals Presents Groundbreaking Pre-Clinical Data at Global Longevity Federation Conference

Published Fri, Mar 22 2024 12:30 PM UTC

The press release highlights that the upcoming poster presentation at the conference will unveil the promising results of Telomir-1 in elongating telomere caps on human normal embryonic fibroblast cells. These telomere caps, located at the ends of chromosomes, serve as protective layers that prevent the erosion and degradation of genetic material during cell division. As cel...
Product Service News

Telomir Pharmaceuticals Pioneering Age Reversal Science with Breakthrough AI Testing Models

Published Thu, Mar 14 2024 12:30 PM UTC

In the perpetual pursuit of the fountain of youth, Telomir Pharmaceuticals is pioneering a groundbreaking approach to age reversal science. Leveraging the power of artificial intelligence (AI) testing models, the company s lead product candidate, Telomir-1, has demonstrated remarkable potential in extending DNA telomeres to reverse age-related conditions. This breakthrough d...
Clinical Study

Revolutionary Breakthrough: Telomir-1 Shows Promising Pre-Clinical Data in Elongating Telomeres and Targeting Age-Related Inflammatory Conditions

Published Thu, Mar 7 2024 1:30 PM UTC

Telomir Pharmaceuticals Presents Exciting Pre-Clinical Data on Telomir-1 at Singapore ConferenceTelomir Pharmaceuticals, in collaboration with Frontage Laboratories, recently unveiled groundbreaking pre-clinical data on their lead development product, Telomir-1, at a prestigious Singapore conference. Telomir s poster presentation captivated the audience, highlighting the pro...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 14.26
PEG (TTM) -

Financial Strength Current
Quick Ratio 15.55
Working Capital Ratio 16.14
Leverage Ratio (MRQ) 0.07
Total Debt to Equity 0.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.92 $
Revenues (TTM) -
Cash Flow (TTM) 0.08 $
Cash 0.08 $
Book Value 0.08 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,937,981
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.